Chelsea Counsel Company’s Prime Medicine PRME Stock Holding History

Chelsea Counsel Company’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.66M	Sell	449,060 -13,280	-3%	-$44.1K	0.7%	34
2026 Q1	$1.61M	Buy	462,340 +235,340	+104%	+$896K	0.72%	33
2025 Q4	$788K	Buy	227,000 +18,790	+9%	+$83.6K	0.34%	52
2025 Q3	$1.15M	Hold	208,210	–	–	0.51%	41
2025 Q2	$514K	Hold	208,210	–	–	0.26%	62
2025 Q1	$414K	Buy	208,210 +21,430	+11%	+$54.7K	0.23%	72
2024 Q4	$545K	Buy	186,780 +108,090	+137%	+$379K	0.28%	61
2024 Q3	$305K	Buy	78,690 +1,000	+1%	+$4.63K	0.15%	84
2024 Q2	$399K	Buy	77,690 +72,690	+1,454%	+$441K	0.2%	72
2024 Q1	$35K	Hold	5,000	–	–	0.02%	124
2023 Q4	$44.3K	Buy	5,000 +4,400	+733%	+$33.9K	0.02%	120
2023 Q3	$5.72K	Hold	600	–	–	﹤0.01%	158
2023 Q2	$8.79K	Hold	600	–	–	﹤0.01%	152
2023 Q1	$7.38K	Hold	600	–	–	﹤0.01%	143
2022 Q4	$11.1K	Buy	+600	New	+$10.8K	0.01%	147

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Chelsea Counsel Company's PRME Position: Q2 2026 in Review

Chelsea Counsel Company reduced its Prime Medicine (PRME) stake by 2.9% in Q2 2026, selling an estimated $44.1K and leaving 449,060 shares worth $1.66M. The position accounts for 0.7% of the portfolio, ranked #34.

Chelsea Counsel Company first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

Chelsea Counsel Company held 449,060 shares of Prime Medicine worth $1.66M as of Q2 2026.
Chelsea Counsel Company sold 13,280 Prime Medicine shares in Q2 2026, an estimated $44.1K.
Prime Medicine made up 0.7% of Chelsea Counsel Company's portfolio in Q2 2026, its #34 holding.
Chelsea Counsel Company first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Chelsea Counsel Company's 13F filing for Q2 2026, filed 12 Aug 2026.